Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4137/MBI.S29459 http://scihub22266oqcxt.onion/10.4137/MBI.S29459 C4803319!4803319!27013887     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27013887&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Microbiol+Insights 2016 ; 9 (ä): 9-19 Nephropedia Template TP {{tp|p=27013887|t=2016. Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria |pdf=|usr=}}{{27013887}} gab.com Text Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria JO: Microbiol Insights http://www.kidney.de/pget.php?&tw=1&pmid=27013887 #FOAvip Currently, drug resistance, especially against cephalosporins and carbapenems, among gram-negative bacteria is an important challenge, which is further enhanced by the limited availability of drugs against these bugs. There are certain antibiotics (colistin, fosfomycin, temocillin, and rifampicin) that have been revived from the past to tackle the menace of superbugs, including members of Enterobacteriaceae, Acinetobacter species, and Pseudomonas species. Very few newer antibiotics have been added to the pool of existing drugs. There are still many antibiotics that are passing through various phases of clinical trials. The initiative of Infectious Disease Society of America to develop 10 novel antibiotics against gram-negative bacilli by 2020 is a step to fill the gap of limited availability of drugs. This review aims to provide insights into the current and newer drugs in pipeline for the treatment of gram-negative bacteria and also discusses the major challenging issues for their management. Twit Text FOAVip Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria ????Microbiol Insights http://www.kidney.de/pget.php?&tw=1&pmid=27013887 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27013887 #FOAvip English Wikipedia <ref>{{Cite pmid|27013887}}</ref> Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria #MMPMID27013887 Taneja N; Kaur H Microbiol Insights 2016[]; 9 (ä): 9-19 PMID27013887show ga Currently, drug resistance, especially against cephalosporins and carbapenems, among gram-negative bacteria is an important challenge, which is further enhanced by the limited availability of drugs against these bugs. There are certain antibiotics (colistin, fosfomycin, temocillin, and rifampicin) that have been revived from the past to tackle the menace of superbugs, including members of Enterobacteriaceae, Acinetobacter species, and Pseudomonas species. Very few newer antibiotics have been added to the pool of existing drugs. There are still many antibiotics that are passing through various phases of clinical trials. The initiative of Infectious Disease Society of America to develop 10 novel antibiotics against gram-negative bacilli by 2020 is a step to fill the gap of limited availability of drugs. This review aims to provide insights into the current and newer drugs in pipeline for the treatment of gram-negative bacteria and also discusses the major challenging issues for their management. äInsights into Newer Antimicrobial Agents Against Gram-negative Bacteri(epmc).pdf DeepDyve Pubget Overpricing